3,149 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Antonelli Financial Advisors LLC

Antonelli Financial Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,149 shares of the medical research company's stock, valued at approximately $821,000. Amgen makes up about 0.7% of Antonelli Financial Advisors LLC's holdings, making the stock its 22nd largest position.

A number of other institutional investors also recently bought and sold shares of AMGN. Blossom Wealth Management lifted its stake in shares of Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after buying an additional 37 shares in the last quarter. Zullo Investment Group Inc. lifted its position in shares of Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after acquiring an additional 37 shares in the last quarter. Trillium Asset Management LLC grew its stake in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock valued at $237,000 after acquiring an additional 37 shares in the last quarter. Brooklyn Investment Group increased its stake in Amgen by 1.1% in the 3rd quarter. Brooklyn Investment Group now owns 3,377 shares of the medical research company's stock worth $1,088,000 after acquiring an additional 38 shares during the last quarter. Finally, Prestige Wealth Management Group LLC increased its holdings in shares of Amgen by 2.8% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 1,387 shares of the medical research company's stock worth $447,000 after buying an additional 38 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares in the company, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $7.52 during mid-day trading on Tuesday, reaching $306.86. The stock had a trading volume of 2,564,825 shares, compared to its average volume of 2,551,876. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $164.85 billion, a P/E ratio of 40.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The business's 50 day moving average price is $298.13 and its 200 day moving average price is $298.50.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. Amgen's payout ratio is 126.09%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMGN. Leerink Partners lowered their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. UBS Group restated a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Redburn Partners cut their target price on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their price target on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of "Hold" and a consensus target price of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.